한글목차

티로신키나아제 억제제 시장 규모는 최근 몇 년간 크게 성장했습니다. 2025년 626억 6,000만 달러에서 2026년에는 678억 5,000만 달러에 이르고, CAGR 8.3%의 성장이 전망되고 있습니다. 지난 몇 년간의 성장은 1세대 티로신 키나아제 억제제의 승인, 만성골수성백혈병의 유병률 증가, 분자생물학의 발전, 병원 약국 네트워크의 확장, 종양학 분야의 연구 개발 증가에 기인하는 것으로 보입니다.

티로신키나아제 억제제(TKI) 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 954억 4,000만 달러에 이르고, CAGR은 8.9%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 차세대 TKI 출시, 신흥 시장 확대, 정밀의료 보급 확대, 온라인 약국 유통의 성장, 바이오텍 기업과 제약사의 협력 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 개인 맞춤형 암 치료, 표적항암제 확대, TKI 임상시험 증가, 병용요법 개발, 경구용 항암제 채택 확대 등을 꼽을 수 있습니다.

암 발병률 증가는 향후 몇 년 동안 티로신 키나아제 억제제(TKI) 시장의 성장을 견인할 것으로 예측됩니다. 암은 모든 장기나 조직에 발생할 수 있는 질병군으로 비정상 세포가 통제할 수 없을 정도로 증식하여 주변 조직으로 침윤하고 다른 장기로 전이되는 특징이 있습니다. 티로신 키나아제 억제제는 암세포의 증식을 촉진하는 티로신 키나아제를 표적치료제로 억제하여 암세포를 선택적으로 억제, 사멸시키는데 사용됩니다. 예를 들어, 2024년 2월 스위스에 본부를 둔 정부 간 기구인 세계보건기구(WHO)는 2050년까지 3,500만 건 이상의 신규 암 환자가 발생할 것으로 예측했습니다. 이는 2022년 추정치인 2,000만 건에서 77% 증가한 수치입니다. 그 결과, 암 발생률 증가는 TKI 시장의 확대를 촉진하고 있습니다.

티로신 키나아제 억제제 시장의 주요 기업들은 치료 성과와 환자 생존율을 향상시키기 위해 표적형 백혈병 억제제 등 첨단 치료제 개발에 집중하고 있습니다. 표적형 백혈병 억제제는 암세포 내 비정상적인 티로신 키나아제 활성을 선택적으로 억제하여 기존 치료법에 비해 부작용을 줄이면서 효능을 높입니다. 예를 들어, 2023년 2월 스웨덴 제약사 엑스스프레이 파마(Xspray Pharma AB)는 미국에 본사를 둔 생명과학 서비스 제공업체 에버사나(EVERSANA)와 파트너십을 맺고 자사의 첫 번째 혁신적 암 치료제인 만성골수성백혈병(CML) 및 급성림프성백혈병(ALL) 치료제인 치료제 '다시녹스'의 미국 출시 및 상용화를 지원했습니다. Dacinoc은 35억 달러 규모의 미국 TKI 시장에서 독보적인 치료 옵션을 제공합니다. ASH 2022에서 발표된 후향적 등록 데이터에 따르면, TKI와 양성자 펌프 억제제(PPI)를 병용한 CML 환자의 5년 생존율은 79%인 반면, TKI 단독 투여 환자의 5년 생존율은 94%로 나타나 치료 전략 최적화의 중요성이 강조됐습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Tyrosine kinase inhibitors (TKIs) are a class of drugs that block specific protein kinases involved in signal transduction pathways. They are used in targeted therapy to eliminate cancer cells while minimizing damage to healthy cells.

The main types of tyrosine kinase inhibitors include BCR-ABL tyrosine kinase inhibitors, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors, and others. BCR-ABL tyrosine kinase inhibitors block the BCR-ABL enzyme, which plays a key role in the development of chronic myelogenous leukemia (CML), and are used as first-line therapy for CML patients. These drugs are distributed through hospital pharmacies, independent pharmacies, and online pharmacies and are applied in the treatment of chronic myeloid leukemia (CML), lung cancer, breast cancer, renal cell carcinoma, and other cancers.

Tariffs have affected the tyrosine kinase inhibitors market by increasing costs for imported active pharmaceutical ingredients (APIs) and advanced drug formulations, particularly impacting segments like BCR-ABL and EGFR inhibitors. Asia-Pacific regions, including China and India, face the most significant challenges due to reliance on manufacturing hubs. The tariffs have led companies to diversify supply chains, increase local production, and accelerate innovation to maintain cost efficiency. While tariffs raise short-term expenses, they may encourage domestic production and self-reliance, potentially benefiting the market in the long term.

The tyrosine kinase inhibitors market research report is one of a series of new reports from The Business Research Company that provides tyrosine kinase inhibitors market statistics, including tyrosine kinase inhibitors industry global market size, regional shares, competitors with a tyrosine kinase inhibitors market share, detailed tyrosine kinase inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the tyrosine kinase inhibitors industry. This tyrosine kinase inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tyrosine kinase inhibitors market size has grown strongly in recent years. It will grow from $62.66 billion in 2025 to $67.85 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to approval of first-generation tkis, growing prevalence of chronic myeloid leukemia, advancements in molecular biology, rise in hospital pharmacy networks, increased r&d in oncology drugs.

The tyrosine kinase inhibitors market size is expected to see strong growth in the next few years. It will grow to $95.44 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to launch of next-generation tkis, expansion of emerging markets, increasing adoption of precision medicine, growth in online pharmacy distribution, collaborations between biotech and pharma companies. Major trends in the forecast period include personalized cancer therapy, expansion of targeted oncology drugs, rising clinical trials for tkis, development of combination therapies, increased adoption of oral oncology medications.

The rising prevalence of cancer is expected to drive the growth of the tyrosine kinase inhibitors (TKIs) market in the coming years. Cancer is a group of diseases that can originate in any organ or tissue, characterized by uncontrolled growth of abnormal cells that invade surrounding tissues and spread to other organs. Tyrosine kinase inhibitors are used in targeted therapies to block tyrosine kinases, which support cancer cell growth, thereby selectively inhibiting and killing cancer cells. For example, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected that over 35 million new cancer cases would occur by 2050, representing a 77% increase from the estimated 20 million cases in 2022. As a result, the increasing incidence of cancer is fueling the expansion of the TKI market.

Leading companies in the tyrosine kinase inhibitor market are focusing on developing advanced therapies, such as targeted leukemia inhibitors, to improve treatment outcomes and patient survival. Targeted leukemia inhibitors selectively block abnormal tyrosine kinase activity in cancer cells, enhancing efficacy while reducing side effects compared to conventional therapies. For instance, in February 2023, Xspray Pharma AB, a Swedish pharmaceutical company, partnered with EVERSANA, a US-based life sciences service provider, to support the U.S. launch and commercialization of Dasynoc, its first innovative cancer therapy for chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Dasynoc offers a distinct treatment option within the $3.5 billion U.S. TKI market. Retrospective registry data presented at ASH 2022 showed a 5-year overall survival rate of 79% for CML patients treated with both a TKI and proton pump inhibitor (PPI) versus 94% for patients on TKI alone, highlighting the significance of optimized treatment strategies.

In February 2025, GSK plc, a UK-based biopharmaceutical company, acquired IDRx, Inc., for $1.15 billion. This acquisition aimed to strengthen GSK's oncology pipeline by gaining access to a precision therapy for gastrointestinal cancers. IDRx, Inc., a US-based clinical-stage biopharmaceutical company, develops a highly selective tyrosine kinase inhibitor targeting KIT mutations in gastrointestinal stromal tumors (GIST).

Major companies operating in the tyrosine kinase inhibitors market are Pfizer Inc, Johnson And Johnson, F. Hoffmann-La Roche AG, AbbVie Inc, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Eli Lilly and Company, Amgen Inc, Boehringer Ingelheim International GmbH, Astellas Pharma Inc, Eisai Co. Ltd, Incyte Corporation, Dr. Reddy's Laboratories Ltd, Exelixis Inc, Blueprint Medicines Corporation, Deciphera Pharmaceuticals LLC, Turning Point Therapeutics Inc, Kura Oncology Inc, ArQule Inc

North America was the largest region in the tyrosine kinase inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tyrosine kinase inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the tyrosine kinase inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tyrosine kinase inhibitors market consists of sales of gleevec, dasatinib (Sprycel), nilotinib (Tasigna), erlotinib (Tarceva), crizotinib (Xalkori), and sunitinib (Sutent). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tyrosine Kinase Inhibitors Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses tyrosine kinase inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tyrosine kinase inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The tyrosine kinase inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: BCR-ABL Tyrosine Kinase Inhibitor; Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors; Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors; Other Types
• 2) By Distribution Channel: Hospital Pharmacy; Independent Pharmacies; Online Pharmacies
• 3) By Application: Chronic Myeloid Leukemia (CML); Lung Cancer; Breast Cancer; Renal Cell Cancer; Other Applications
• Subsegments:
• 1) By BCR-ABL Tyrosine Kinase Inhibitor: Imatinib; Dasatinib; Nilotinib; Bosutinib; Ponatinib
• 2) By Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors: Gefitinib; Erlotinib; Afatinib; Osimertinib; Dacomitinib
• 3) By Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors: Sorafenib; Sunitinib; Pazopanib; Axitinib; Regorafenib
• 4) By Other Types: Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors; RET Tyrosine Kinase Inhibitors; Fibroblast Growth Factor Receptor (FGFR) Inhibitors; Other Emerging Tyrosine Kinase Inhibitors
• Companies Mentioned: Pfizer Inc; Johnson And Johnson; F. Hoffmann-La Roche AG; AbbVie Inc; Bayer AG; Novartis AG; Bristol-Myers Squibb Company; AstraZeneca Plc; Eli Lilly and Company; Amgen Inc; Boehringer Ingelheim International GmbH; Astellas Pharma Inc; Eisai Co. Ltd; Incyte Corporation; Dr. Reddy's Laboratories Ltd; Exelixis Inc; Blueprint Medicines Corporation; Deciphera Pharmaceuticals LLC; Turning Point Therapeutics Inc; Kura Oncology Inc; ArQule Inc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Tyrosine Kinase Inhibitors Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Tyrosine Kinase Inhibitors Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Tyrosine Kinase Inhibitors Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Tyrosine Kinase Inhibitors Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Artificial Intelligence & Autonomous Intelligence
  • 4.1.2 Biotechnology, Genomics & Precision Medicine
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Personalized Cancer Therapy
  • 4.2.2 Expansion Of Targeted Oncology Drugs
  • 4.2.3 Rising Clinical Trials For Tkis
  • 4.2.4 Development Of Combination Therapies
  • 4.2.5 Increased Adoption Of Oral Oncology Medications

5. Tyrosine Kinase Inhibitors Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Oncology Clinics
• 5.3 Cancer Research Centers
• 5.4 Specialty Pharmacies
• 5.5 Home Healthcare Providers

6. Tyrosine Kinase Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Tyrosine Kinase Inhibitors Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Tyrosine Kinase Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Tyrosine Kinase Inhibitors Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Tyrosine Kinase Inhibitors Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Tyrosine Kinase Inhibitors Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Tyrosine Kinase Inhibitors Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Tyrosine Kinase Inhibitors Market Segmentation

• 9.1. Global Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, Other Types
• 9.2. Global Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacy, Independent Pharmacies, Online Pharmacies
• 9.3. Global Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Renal Cell Cancer, Other Applications
• 9.4. Global Tyrosine Kinase Inhibitors Market, Sub-Segmentation Of BCR-ABL Tyrosine Kinase Inhibitor, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib
• 9.5. Global Tyrosine Kinase Inhibitors Market, Sub-Segmentation Of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Gefitinib, Erlotinib, Afatinib, Osimertinib, Dacomitinib
• 9.6. Global Tyrosine Kinase Inhibitors Market, Sub-Segmentation Of Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Sorafenib, Sunitinib, Pazopanib, Axitinib, Regorafenib
• 9.7. Global Tyrosine Kinase Inhibitors Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors, RET Tyrosine Kinase Inhibitors, Fibroblast Growth Factor Receptor (FGFR) Inhibitors, Other Emerging Tyrosine Kinase Inhibitors

10. Tyrosine Kinase Inhibitors Market Regional And Country Analysis

• 10.1. Global Tyrosine Kinase Inhibitors Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Tyrosine Kinase Inhibitors Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Tyrosine Kinase Inhibitors Market

• 11.1. Asia-Pacific Tyrosine Kinase Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Tyrosine Kinase Inhibitors Market

• 12.1. China Tyrosine Kinase Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Tyrosine Kinase Inhibitors Market

• 13.1. India Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Tyrosine Kinase Inhibitors Market

• 14.1. Japan Tyrosine Kinase Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Tyrosine Kinase Inhibitors Market

• 15.1. Australia Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Tyrosine Kinase Inhibitors Market

• 16.1. Indonesia Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Tyrosine Kinase Inhibitors Market

• 17.1. South Korea Tyrosine Kinase Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Tyrosine Kinase Inhibitors Market

• 18.1. Taiwan Tyrosine Kinase Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Tyrosine Kinase Inhibitors Market

• 19.1. South East Asia Tyrosine Kinase Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Tyrosine Kinase Inhibitors Market

• 20.1. Western Europe Tyrosine Kinase Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Tyrosine Kinase Inhibitors Market

• 21.1. UK Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Tyrosine Kinase Inhibitors Market

• 22.1. Germany Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Tyrosine Kinase Inhibitors Market

• 23.1. France Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Tyrosine Kinase Inhibitors Market

• 24.1. Italy Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Tyrosine Kinase Inhibitors Market

• 25.1. Spain Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Tyrosine Kinase Inhibitors Market

• 26.1. Eastern Europe Tyrosine Kinase Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Tyrosine Kinase Inhibitors Market

• 27.1. Russia Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Tyrosine Kinase Inhibitors Market

• 28.1. North America Tyrosine Kinase Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Tyrosine Kinase Inhibitors Market

• 29.1. USA Tyrosine Kinase Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Tyrosine Kinase Inhibitors Market

• 30.1. Canada Tyrosine Kinase Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Tyrosine Kinase Inhibitors Market

• 31.1. South America Tyrosine Kinase Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Tyrosine Kinase Inhibitors Market

• 32.1. Brazil Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Tyrosine Kinase Inhibitors Market

• 33.1. Middle East Tyrosine Kinase Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Tyrosine Kinase Inhibitors Market

• 34.1. Africa Tyrosine Kinase Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Tyrosine Kinase Inhibitors Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Tyrosine Kinase Inhibitors Market Regulatory and Investment Landscape

36. Tyrosine Kinase Inhibitors Market Competitive Landscape And Company Profiles

• 36.1. Tyrosine Kinase Inhibitors Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Tyrosine Kinase Inhibitors Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Tyrosine Kinase Inhibitors Market Company Profiles
  • 36.3.1. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. AbbVie Inc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

37. Tyrosine Kinase Inhibitors Market Other Major And Innovative Companies

• Novartis AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Eli Lilly and Company, Amgen Inc, Boehringer Ingelheim International GmbH, Astellas Pharma Inc, Eisai Co. Ltd, Incyte Corporation, Dr. Reddy's Laboratories Ltd, Exelixis Inc, Blueprint Medicines Corporation, Deciphera Pharmaceuticals LLC, Turning Point Therapeutics Inc, Kura Oncology Inc

38. Global Tyrosine Kinase Inhibitors Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Tyrosine Kinase Inhibitors Market

40. Tyrosine Kinase Inhibitors Market High Potential Countries, Segments and Strategies

• 40.1 Tyrosine Kinase Inhibitors Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Tyrosine Kinase Inhibitors Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Tyrosine Kinase Inhibitors Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer